Teva nasal allergy spray approved; Topical formulation of ibuprofen under development;

> The FDA approved Teva's ($TEVA) QNASL for the treatment of nasal symptoms of allergic rhinitis. The company says it is the first nasal allergy spray approved for children as young as four years old. It is a lower dose formulation of the medication meant for adults. Release

> Strategic Science and Technologies (SST) signed an agreement that gives an unnamed, large over-the-counter healthcare company an exclusive option to the obtain U.S. commercial rights to SST's topical formulation of ibuprofen once it gets approved by the FDA. Release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.